Analyzing Initial Phase 1b Heart-2 Results for VERVE-102 in HeFH and Premature CAD from Verve Therapeutics

Executed on:Jul 29, 2025 10:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Oregon Health & Science University

Associate Director of the Center for Preventive Cardiology and Professor at Oregon Health & Science University with a specific clinical focus on inherited lipid disorders.
Personally manages ~500 patients with HeFH within the center for Preventive Cardiology.
Research focuses on PCSK9 physiology and its impact on lipoprotein metabolism; engaged in clinical trials testing novel lipid modulating therapeutics.

Interview Goal

The interview will explore early safety and efficacy data from the Phase 1b Heart-2 clinical trial evaluating VERVE-102, an in vivo base editing therapy designed to durably reduce LDL-C in patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD). Topics include the dose-dependent effects on LDL-C and PCSK9 levels, safety profile, the potential for a single-dose paradigm shift in cardiovascular treatment, and future clinical and regulatory milestones.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.